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Fat tissue was initially described for its endocrine and metabolic function. Over the last
two decades increasing evidence indicated a close interaction with the immune system.
Partly responsible for this immune modulatory function are soluble factors released
by the fat tissue, most prominently the so-called adipokines. These discoveries led
to the question how adipokines influence inflammatory diseases. Linking inflammation
and adipose tissue, Crohn’s disease, a chronic inflammatory bowel disease, is of
particular interest for studying the immune modulatory properties of adipokines since it is
characterized by a hyperplasia of the mesenteric fat that subsequently is creeping around
the inflamed segments of the small intestine. Thus, the role of several adipokines in the
creeping fat as well as in intestinal inflammation was recently explored. The present review
selected the four adipokines adiponectin, apelin, chemerin, and leptin and provides a
working model based on the available literature how these factors participate in the
maintenance of intestinal immune homeostasis.
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INTRODUCTION
Adipokines represent a group of mediators primarily released by adipocytes that modulate a variety
of metabolic functions within the fat tissue and additional organs such as liver, brain and muscle.
In addition to the metabolic functions, a regulatory role within the immune system was identified
early on for a number of adipokines. This includes adiponectin which in first reports was shown to
suppress mature macrophage function (1) as well as leptin that was identified as a T cell stimulatory
factor (2). These initial publications induced a plethora of studies exploring the impact of various
adipokines in several inflammatory diseases. Why is intestinal inflammation of particular interest
for the regulatory function of adipokines?
In Crohn’s disease, one subtype of inflammatory bowel disease (IBD), characteristic changes of
the mesenteric fat suggest that the mesenteric fat might play a central immune modulatory role in
the pathogenesis of Crohn’s diseases (3). In this disease, the mesenteric fat becomes hyperplastic
and is creeping around the inflamed segments of the small intestine, suggesting a direct role
of this fat tissue compartment in Crohn’s disease. In order to provide a concise overview how
adipokines regulate intestinal inflammation, we here selected adipokines for which experimental
data in intestinal inflammation were available. Thus, we chose apelin, adiponectin, chemerin, and
leptin. In order to include the relevant literature, we chose the names of the respective adipokine
in combination with either colitis, IBD, Crohn’s disease, or ulcerative colitis as search terms in
PubMed. This review will first focus on the selected adipokines (summary provided in Table 1),
namely apelin, adiponectin, chemerin and leptin, and then provide a disease-relevant working
model.
Weidinger et al. Adipokines in Intestinal Inflammation
TABLE 1 | Adipokines and the regulatory effect on intestinal homeostasis.
Adipokine Effect on mucosal homeostasis References
Adiponectin Function




Globular adiponectin has been shown to enhance intestinal epithelial cell proliferation and prevented these cells
from apoptosis. In line, adiponectin−/− mice developed more severe DSS-induced colitis accompanied by a




The data on the in vivo role are controversial. Fayad et al. provided evidence suggesting a pro-inflammatory role
for adiponectin in DSS- as well as TNBS-induced colitis. Conversely, Nishihara et al. found the opposite. In
addition, work by Sideri et al. demonstrated that silencing of AdipoR1 was followed by deterioration of
TNBS-induced colitis. These obvious discrepancies might be explained by differences in knockout mice.
(7–10)
Human data
Adiponectin has been shown to be upregulated in the creeping fat of Crohn’s disease as compared to
non-creeping fat of Crohn’s disease, ulcerative colitis and healthy controls.
(11)
Apelin Function




Apelin is upregulated in the intestinal epithelial cells of colitic mice.
Apelin administration ameliorated colitis in Il10−/− mice by enhancing intestinal lymphatic function.
(13, 14)
Human data
Apelin is upregulated in the intestinal epithelial cells of IBD patients.
Apelin is highly expressed in the mesenteric adipose tissue of Crohn’s disease patients.
(12, 15)
Chemerin Function
Chemerin has been shown to serve as chemoattractant for cells of the innate immune system.
(16)
in vivo models
Administration of chemerin aggravated DSS-induced colitis and was associated with a decrease in
anti-inflammatory macrophages. Accordingly, mice deficient in the chemerin receptor, chemokine-like receptor 1
(CMKLR1), develop colitis in a delayed course, ultimately resulting in similar disease severity.
(17, 18)
Human data
Chemerin was elevated in the serum of IBD patients.
(19)
Leptin Function




Leptin has been shown to induce an increased intestinal epithelial cell proliferation. In addition, intestinal epithelial
cells produce leptin and luminal leptin vice versa activates the NF- κB pathway in intestinal epithelial cells. In line,
rectal application in vivo results in intestinal inflammation. Leptin signaling is required for in vitro polarization of
Th17 cells as leptin receptor (Lepr) deficient T cells display decreased STAT3 signaling and consecutively less
RORγt expression and impaired IL-17 and IFNγ production.
(21–23)
in vivo models
Leptin-deficient ob/ob mice are protected from experimental colitis. Colitis induction depends on the activation of




Leptin is upregulated in the mesenteric fat of Crohn’s disease patients. The presence of leptin in the mesenteric fat
favors the polarization of tissue macrophages toward an anti-inflammatory phenotype.
(28, 29)




Early on, apelin has been shown to be elevated in the colonic
tissue of mice suffering from colitis as well as in humans
with IBD. Apelin was mainly expressed by epithelial cells and
addition of synthetic apelin in cell culture increased epithelial cell
proliferation (12). More recently, apelin was described to play a
significant role in the development as well as the stabilization of
lymphatic vessels (13, 14). Remarkably, defects in the lymphatic
transport of the mesentery have previously been suggested to
be involved in the pathogenesis of Crohn’s disease. This is
reflected by an increased density of lymphatic vessels as well
as the presence of tertiary lymphoid organs in the mesentery
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of Crohn’s disease patients (30, 31). Accordingly, apelin was
shown to be highly expressed in the mesenteric adipose tissue
of Crohn’s disease patients. In addition, the administration of
apelin to Il10−/− mice with established colitis resulted not only
in an amelioration of disease by lowering the production of
pro-inflammatory cytokines such as TNFα, IL-6, and IL-1β but
furthermore enhanced intestinal lymphatic function. This was
shown by an increased lymphatic vessel density. In addition,
lymphangiography indicated an augmented lymphatic drainage
(15). Based on these findings, one can propose a regenerative
function of apelin on intestinal epithelial cells as well as a
supportive role with regard to intestinal lymphatic drainage.
Adiponectin
The adipokine adiponectin plays a key role in regulating insulin
sensitivity and had previously been shown to play an anti-
inflammatory role in atherosclerosis (4). The study by Yamamoto
et al. analyzed the adiponectin expression in the creeping fat
of Crohn’s disease patients, that revealed an upregulation of
adiponectin expression in creeping fat of Crohn’s disease patients
when compared to non-creeping fat of Crohn’s disease patients
as well as fat from ulcerative colitis patients or controls (11).
A study by Fayad et al. explored the function of adiponectin
in intestinal inflammation by subjecting adiponectin-deficient
animals to two models of experimental colitis, the model of
dextran sulfate sodium (DSS)- and the model of trinitrobenzene
sulphonic acid (TNBS)-induced colitis. Adiponectin was shown
to rather induce the production of pro-inflammatory cytokines
in the colon as adiponectin stimulation of colon organ cultures
of DSS-treated mice resulted in increased production of IL-
6 and MIP-2, whereas adiponectin-deficient APN knock out
mice were protected from experimental colitis. Thus, these
data were somewhat contrary to the findings described for
atherosclerosis (8). A second study by Nishihara et al. explored
again adiponectin-deficient mice in the DSS and TNBS model
of colitis. In contrast to the previous study, adiponectin
protected from inflammation, possibly mediated by a direct anti-
inflammatory effect on the colonic epithelial cells (7). These
discrepancies between the two studies as well as in several in vitro
studies are most likely due to different types of knockout mice or
adiponectin used (9).
In line with the first study, Ogunwobi and colleagues provide
data analyzing the effect of adiponectin on colon epithelial
cells by using the colonic epithelial cell line HT-29 and by
carefully distinguishing globular adiponectin from full-length
adiponectin. Remarkably, in particular globular adiponectin
mediated pro-proliferative as well as pro-inflammatory effects
through activation of extracellular-signal regulated kinase (ERK),
p38 mitogen-activated protein kinase (MAPK) NF-κB signaling
on colonic epithelial cells (5). When the human NCM60
epithelial cell line was exposed to fat-conditionedmedia obtained
from IBD patients, cells showed a reduced expression of
adiponectin receptor 1 (AdipoR1). Silencing of AdipoR1 in mice
resulted in an exacerbation of TNBS-induced colitis (10).
In a recent study, adiponectin-deficient mice treated with
DSS exhibited more severe colitis accompanied by an increased
presence of activated B cells, pro-inflammatory cytokines such as
IL-1β, IL-4, and IL-6 and increased STAT3 signaling in the colon.
The epithelium of the knockout animals revealed a decrease
in cell proliferation as well as increased apoptosis and cellular
stress. In in vitro experiments these effects could be reversed
by adiponectin. These data are supporting the concept that
adiponectin maintains intestinal homeostasis (6).
Chemerin
Chemerin has been shown to serve as chemo-attractant for
cells of the innate immune system (16). Serum from Crohn’s
disease (n = 230), ulcerative colitis patients (n = 80), and
healthy controls (n = 80) was recently compared for the
expression of chemerin and adiponectin. Chemerin was elevated
in IBD patients, whereas adiponectin was decreased (19). An
in vivo study furthermore indicated that the administration of
chemerin resulted in aggravation of DSS-induced colitis in mice
by augmenting TNFα and IL-6 production, whereas a decrease
in IL-10−producing anti-inflammatory macrophages could be
detected. This could be confirmed in vitro, where the presence
of chemerin prevented macrophages from polarizing into an
anti-inflammatory phenotype resulting in impaired expression
of Arginase-1 and IL-10 (17). The chemokine-like receptor
1 (CMKLR1) is the receptor for chemerin. Mice deficient in
CMKLR1 developed DSS-induced colitis in a delayed time
course, albeit ultimately presenting with a similar disease activity
(18).
Leptin
Leptin was initially identified as a satiety factor (20, 32). Work
by Lord and colleagues revealed that the adipokine leptin
supports T cell proliferation and results in increased T helper
cell type 1 (Th1) and in suppressed Th2 cytokine production.
In addition, administration of leptin to starved mice resulted
in an abrogation of starvation-induced immunosuppression (2).
The additional characterization of three children with congenital
leptin deficiency indicated that leptin substitution not only
reversed their metabolic dysfunction including insulin resistance
and fatty liver degeneration, but furthermore increased the
number of circulating CD4+ T cells as well as their proliferative
capacity (33). These findings raised the question whether
leptin exerts a modulating effect on autoimmune diseases.
First evidence was provided from the model of experimental
autoimmune encephalomyelitis. Here, leptin-deficient (ob/ob)
mice were protected from T cell-mediated neuronal damage
and leptin substitution augmented the disease susceptibility in
mice. Additional work on the same model revealed that CNS-
infiltrating T cells themselves are able to produce leptin and that
this effect could be blocked by an anti-leptin receptor antibody
(34, 35).
In an early study, systemic leptin concentrations were
determined during the course of acute experimental colitis. In
this study, the concentration of leptin in the plasma increased
in TNBS-induced colitis and indomethacin-induced ileitis and
correlated with disease severity. However, this observed increase
was only transient and returned to control concentrations over
time (36). The association of a distinct disease to plasma levels has
proven difficult for several disease entities in the past. However,
independent studies revealed a strong up-regulation of leptin
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expression in the mesenteric fat of Crohn’s disease patients (28,
37).
In our own work, we were able to demonstrate that leptin-
deficient ob/ob mice are protected from DSS-induced colitis and
that leptin administration reverses disease susceptibility in mice
(24). To confirm the previously established concept that leptin
mediates pro-inflammatory effects, at least partly, via T cells, we
performed a T cell transfer model of colitis and transferred naive
CD4+ T cells lacking the signaling Ob-Rb-isoform of the leptin
receptor. In fact, the development of colitis was significantly
delayed using this approach, indicating that the stimulatory effect
of leptin plays a crucial role in this model (25). Additional data
showing that ob/obmice are protected in models driven by either
Th1 (TNBS) or Th2 (oxazolone) cells underline that the T cell-
stimulating capacity of leptin is important for the observed effects
(27). However, this enhancing factor does not apply for all T
cell subpopulations, since leptin has been shown to inhibit the
proliferation of regulatory T (Treg, FoxP3
+CD4+CD25+) cells.
Accordingly, the absence of leptin, as demonstrated for ob/ob
and db/db mice (mice deficient for the signaling Ob-Rb isoform
of the leptin receptor), resulted in an increased proliferation
of functional Treg cells (38). Likewise, Reis and colleagues
could demonstrate that Leprfl/fl−CD4-Cre mice harboring a
conditional knock out of the leptin receptor in their CD4+ T cell
compartment also showed higher frequencies of FOXP3+ Treg
cells under steady state conditions. Importantly, Lepr-deficient
T cells displayed a severe defect in Th17 differentiation due to
a decreased activation of the STAT3 signaling cascade, resulting
in impaired cytokine production of IL-17 and IFNγ, which
protected recipient Rag-−/− mice receiving Lepr-deficient T cells
from transfer colitis (23).
Data from the experimental autoimmune encephalomyelitis
model have previously indicated that leptin produced by T cells
might play a key role in mediating disease severity (23, 35).
Thus, we performed again the T cell transfer model of colitis
and chose this time naive T cells isolated from ob/ob mice
as disease-inducing cell population in comparison to wild-type
cells. In contrast to the data cited above, no differences were
observed with regard to disease severity or cytokine production,
implying that leptin produced by T cells is irrelevant for intestinal
inflammation (26).
Recent data indicate that the administration of a pegylated
leptin antagonist (PG-MLA) was sufficient to protect from
chronic experimental colitis. Amelioration of colitis was here
associated with a decrease in the expression of mucosal pro-
inflammatory cytokines and an increase of mucosal Treg cells
(39).
Having shown that leptin modulates intestinal inflammation
via the T cell compartment, the question arose whether there is
an additional effect on epithelial cells. The leptin receptor (Ob-
Rb) is in fact expressed in human colonic tissue as well as on
the HT-29 colon cancer cell line. Stimulation of HT-29 cells with
leptin was followed by activation of p42/44 MAPK as well as
increased proliferation in vitro and in vivo (21). An interesting
aspect was added by the study of Sitaraman and colleagues that
were able to demonstrate that inflamed colonic epithelial cells
produce and release leptin into the intestinal lumen. The presence
of luminal leptin resulted in the activation of the NF- κB pathway
in intestinal epithelial cells. Rectal application of leptin was
followed by intestinal inflammation and epithelial wall damage
(22). Following up on these luminal effects, Hoda et al. analyzed
the effect of luminal leptin on ion transport capacities under
inflammatory conditions. Human intestinal epithelial cells (T84)
as well as intestinal tissue from a rat model of chemotherapy-
induced enterocolitis were analyzed in Ussing chambers. These
served to determine the transepithelial short-circuit current I(sc).
The presence of leptin resulted in an increase of basal I(sc) of T84
cells, which was mediated by activation of theMAPK pathway. In
line, in the enterocolits model luminal leptin equally induced an
increase in I(sc), that was more prominent in the proximal colon
(40).
A recent study was able to link leptin, cell metabolism and
intestinal epithelial function. The authors provided evidence
indicating that leptin is able to induce lipid droplet formation
in intestinal epithelial cells (IEC-6). This was accompanied
by an increased production of CXCL1/CINC-1, CCL2/MCP-
1, and TGFβ. In line with previous data, leptin induced
cell proliferation. The process of lipid droplet induction and
the associated effects depended on the mammalian target of
rapamycin (mTOR) pathway, since it was completely abrogated
in the presence of rapamycin (41). Thus, one can conclude
that leptin, very similar to adiponectin, exerts direct effects
on intestinal epithelial cells and consequently plays a role in
intestinal homeostasis.
HOW GETS THE MESENTERIC FAT TISSUE
STIMULATED AND ADIPOKINES
RELEASED?
The question arises how the mesenteric fat gets involved in
the first place. Courageous proposals suggest that changes
in the mesenteric fat tissue might in fact be the initiating
event of Crohn’s disease. However, this is not only difficult to
proof but it also seems to be more likely that the transmural
inflammation and consecutive chronic bacterial translocation is
the initiating factor for these changes. Crohn’s disease, in contrast
to ulcerative colitis, presents with a transmural inflammation
and can also affect the small intestine. Several experimental
models as well as studies in humans provided evidence of
an increased translocation of bacteria into the mesenteric fat
(42, 43). Previous data had already proven that adipocytes as
well as preadipocytes express functional receptors of the innate
immune system including toll-like receptors (Tlr) and nucleotide
oligomerization domains 1 (NOD1) and 2 (NOD2) (44, 45).
Accordingly, while wild type mice featured an up-regulation of
pro-inflammatory mediators in chronic DSS colitis, Myd88−/−
mice, thus mice with a dysfunctional innate immune system,
failed to respond to these translocalizing bacteria and showed a
significantly increased mortality, suggesting that the mesenteric
fat serves as a potential second barrier (42, 46). In line, wild-type
mice revealed an up-regulation of leptin in the mesenteric fat,
whereas this was not observed in Tlr9−/− mice. However, IL-6
production was unaffected by the absence of Tlr9 (47), indicating
that other innate receptors contribute to the effects described
before (42).
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FIGURE 1 | Regulatory effect of selected adipokines on intestinal homeostasis. The figure illustrates at which layer of the intestinal wall the selected adipokines exert
their respective regulatory function. Blue indicates the intestinal epithelial layer. Adiponectin, apelin and leptin have been shown to enhance cell proliferation and
enhance barrier function. The majority of these data derive from in vitro data, thus it remains open how these adipokines contribute to the complex crosstalk between
epithelial cells and immune cells in vivo. Green indicates the lamina propria with all cell populations included. Chemerin has been shown here to attract innate immune
cells resulting in a deterioration of colitis. Leptin induces T cell proliferation thus enhancing inflammation. Yellow indicates the mesenteric fat tissue. Adiponectin, apelin
and leptin are all up-regulated in this compartment. Apelin enhances the function of the lymphatic vessels, that are known to be dysfunctional in Crohn’s disease.
Leptin strongly influences the polarization of infiltrating monocytes toward rather anti-inflammatory macrophages.
What is the subsequent effect of adipokines produced
within the mesenteric adipose tissue? Leptin has been shown
to not only modulate the polarization of the T helper cell
compartment but to equally affect together with adiponectin the
myeloid compartment. Leptin as well as adiponectin favored the
polarization of anti-inflammatory macrophages, the dominant
macrophage population detectable in creeping fat of Crohn’s
disease patients (29). In addition, as described above for mice
(42) and patients with Crohn’s disease (43), the mesenteric fat
develops an effector response to the translocalizing antigens.
Remarkably, a dysfunction of this effector response, as discussed
above for the Myd88−/− mice, results in an increased mortality,
thus suggesting a primarily protective function. Together this
fits into the concept that the mesenteric fat represents a second
barrier and thereby prevents the Crohn’s disease patient from
continuous bacteremia (48, 49).
A summary of the effects mediated by adipokines is provided
in Figure 1.
CONCLUSIONS
Continuous work over the last two decades has substantially
provided insights into the regulation of adipokines and intestinal
inflammation. The data discussed for adiponectin, apelin,
chemerin, and leptin within this review indicate a complex
specific function for each individual adipokine in the regulation
of intestinal inflammation. However, the summary also reveals
the shortcomings of our current understanding. Thus, the
complex interplay between the adipose tissue and the immune
system presents a hot topic for current research. In our view,
it is rather unlikely that adipokines will serve as therapeutic
option for patients with IBD. Nevertheless, the overall metabolic
condition of a patient, e.g., body mass index, presence of
diabetes, might strongly influence the adipokine response on
one hand, on the other hand, anti-inflammatory treatment in
IBD patients might result in direct changes of the adipokine
and thus metabolic profile. Therefore, this particular cross-
regulation will become even more important in the foreseeable
future.
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